cisplatin + nivolumab + romidepsin

This is an investigational combination therapy consisting of three agents—cisplatin, nivolumab, and romidepsin—used together in clinical trials for the treatment of metastatic triple negative breast cancer (TNBC) and BRCA mutation-associated locally recurrent or metastatic breast cancer. - **Cisplatin** is a platinum-based chemotherapy that causes DNA crosslinking and apoptosis in rapidly dividing cells. - **Nivolumab** is a monoclonal antibody immune checkpoint inhibitor targeting programmed death-1 (PD-1), enhancing T-cell mediated anti-tumor responses. - **Romidepsin** is a histone deacetylase inhibitor (HDACi) that modulates gene expression by altering chromatin structure, leading to cell cycle arrest and apoptosis in malignant cells. The rationale for this combination includes potential synergistic effects between epigenetic modulation (romidepsin), cytotoxic chemotherapy (cisplatin), and immune activation (nivolumab). This triplet regimen has been studied in early-phase clinical trials but has not received regulatory approval as a fixed combination[1][2][8].